In terms of cirrhosis and drug development, the earlier conversations identified two goals: Focus on NASH cirrhosis as a possible an easier and faster path to approval than the traditional “start with F2/3” approach, and push to move the codification of disease knowledge and best practices from guidance documents that might be upgraded every five years to a real-time, on-line document similar to what we see today in Hepatitis C. As the conversation wraps up, all four panelists (Stephen Harrison, Louise Campbell, Jörn Schattenberg and Roger Green) consider what they each might do to push these ideas forward. If you are captivated or even intrigued by the earlier parts of the episode, listen to this conversation asking what you, yourself, can do to help bring about the changes Fatty Liver stakeholders need.
